ACEI and ARB use in CKD has been available for over three decades, but it is still underutilized. Now, a new clinical ...

To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

A new aldosterone synthase inhibitor added to SGLT2 inhibitors reduces uncontrolled blood pressure in patients with chronic kidney disease, according to the results of a phase 2 trial.

"Overall, the comprehensive meta-analysis highlights that SGLT2 inhibitors are effective across a wide range of kidney ...

A new study published in the Journal of American Heart Association found that the risk of sudden cardiac arrest (SCA) may be ...

Enhanced CKD diagnosis and treatment could reduce dialysis, cardiovascular events, and mortality, while decreasing healthcare costs and environmental impact. CKD affects 13% of the global population, ...

The phase 2 EXPLORE-CKD trial is examining the efficacy and safety of lorundrostat in addition to SGLT2 inhibitors in patients with hypertension and CKD with albuminuria.

An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney ...

A new Lancet study led by University of Glasgow flags CKD as the 9th leading cause of death globally, urging early detection and prevention in India's fight against this "silent" disease.

The number of adults living with chronic kidney disease (CKD) has more than doubled since 1990, reaching nearly 800 million ...

An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney ...

Fish delivers protein, and when you choose a fatty fish like tuna, salmon or trout, you're also getting omega-3 fatty acids.